FDA grants Adcetris breakthrough designation in Hodgkin lymphoma

New York-listed Seattle Genetics has been given breakthrough therapy designation for Adcetris (brentuximab vedotin), in combination with chemotherapy, for the first-line treatment of patients with advanced classical Hodgkin lymphoma.

The company announced positive topline results from the Phase III ECHELON-1 trial in June 2017 and full data will be presented at a conference in early December.

The drug is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma.